Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
US Judge Dismisses Gautam Adani Criminal Charges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
WALTHAM, Mass., Feb. 20, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018)
Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, March 6, 2018 at 8:00 a.m. CT / 9:00 a.m. ET. The conference immediately precedes the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 38th Annual Health Care Conference – Boston, MA (March 12-14, 2018)
Mr. Gridley will present a corporate overview on Wednesday, March 14, 2018 at 8:40 a.m. ET.
To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
